Government and the pursuit of rigorous drug testing in Major League Baseball: a study in political negotiation and reciprocity Online publication date: Tue, 22-May-2007
by Bryan E. Denham
International Journal of Sport Management and Marketing (IJSMM), Vol. 2, No. 4, 2007
Abstract: Since June 2002, the point at which Sports Illustrated published a cover story about widespread steroid use in Major League Baseball, US legislators and baseball officials have sparred over the use of performance-enhancing drugs. This paper examines political negotiations that took place in 2005, focusing on how the threat of legislative acts, such as the Drug Free Sports Act (H.R.1862), the Professional Sports Integrity Act (H.R.2516), the Clean Sports Act (S.1114, H.R.2565) and the Professional Sports Integrity and Accountability Act (S.1334), may have led Major League Baseball and the Major League Baseball Players Association (MLBPA) to ratify a more rigorous drug-testing policy than both would have preferred. The article suggests that while professional baseball players may need to be more careful under the new joint drug agreement, reached in December 2005, more expensive substances, such as human growth hormone, will continue to be used.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Sport Management and Marketing (IJSMM):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook